BioSpace News Archive

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2022.

Soligenix, Inc. announced today that the Company has been invited by the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures to submit a full contract proposal for the development of single-vial, adjuvanted, heat stable subunit vaccines to prevent filovirus infection.

Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that it plans to host a conference call on Thursday, November 3, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 3, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2022.

Monopar Therapeutics Inc. will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced that results from the Waldenstrom macroglobulinemia (“WM”) cohort and other interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy being conducted at Fred Hutchinson Cancer Center (“Fred Hutch”), will be presented at the 11th International Workshop for Waldenstrom’s Macroglobulinemia (“IWWM-11”) taking place in Madrid, Spain.

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended September 30, 2022.

Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2022.

Prestige Biopharma group comprised of Prestige Biopharma Limited and Prestige Biologics Co., Ltd. is pleased to announce that it will be appearing at CPhI Frankfurt 2022 on 1-3 November at Messe Frankfurt, Germany.

BioInvent further strengthened its financial position in the third quarter through a directed share issue.